Follow Danaher to never miss an important update.
Citigroup analyst raised their price target from $230 to $270 while keeping a buy rating on the stock. This move reflects growing confidence in the company's recovery as the market for drug-making tools and lab supplies begins to stabilize. The new target is higher than the average analyst target of $245 and suggests the stock has room to rise from its current price of about $228.
Source: Citigroup
After Danaher reported its October results, we updated our fair value and raised our projections for core sales growth to 3.0%. We have added the shift toward software and AI-driven laboratory research to the growth drivers we track following the company's new partnership with NVIDIA. We also reset our expectations for profit margins in the diagnostics division to 29.5% and added a specific monitor for how the business accounts for customer tariff refunds.
Danaher reported adjusted earnings of $2.11 per share, beating the $1.92 analysts expected. While total revenue of $6.55 billion was roughly in line with targets, the important detail is that core revenue excluding respiratory tests grew 5.5 percent. This suggests that the long slump in bioprocessing, the tools and supplies used to manufacture complex biologic drugs, is finally turning into a recovery.
This is a vital signal for the company because these supplies are high-margin and recurring. When drug companies start buying more filters and equipment again, it confirms that the post-pandemic period of sitting on extra inventory is over. With cash flow reaching $1.6 billion for the quarter, the business is showing it can generate plenty of capital to reinvest as its core markets find their footing again.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Morgan Stanley raised its target for the stock to $240 from $220. This move brings the firm's outlook slightly above the average analyst target of $231. While the firm is more optimistic about the stock's price, it did not change its overall rating. These target tweaks are routine adjustments and do not change our view that the company's value depends on the recovery of its bioprocessing business, which sells the tools used to manufacture complex drugs.
Source: Morgan Stanley
Danaher is partnering with NVIDIA to integrate AI technology into its scientific instruments and lab workflows. The goal is to create autonomous labs that can handle complex research tasks with less human intervention, which could significantly speed up the time it takes for pharmaceutical companies to develop new drugs.
This move builds on Danaher's plan to launch its first autonomous lab next year. For a long-term owner, this is a clear sign that the company is trying to make its equipment more essential by adding software that rivals may struggle to match. If Danaher can successfully embed NVIDIA's AI into its machines, it makes its products harder for labs to swap out, protecting the high-margin supply sales that drive most of its profit.
Source: PRNewsWire
Management has cleared their own profit targets for eight straight quarters. This record shows they set conservative bars and have a tight grip on their costs even when sales are slow.
| Expectation | |
|---|---|
| EPS | $2.49 |
| Revenue | $7.49B |